Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy

Author： Greiner Roger-Axel  

Publisher： Informa Healthcare

ISSN： 0882-0538

Source： Seminars in Ophthalmology, Vol.16, Iss.4, 2001-12, pp. : 218-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost and Effectiveness of Therapy for Wet Age-Related Macular Degeneration in Routine Clinical Practice

By  

Ophthalmologica, Vol. 230, Iss. 1, 2013-06 ,pp. : 34-42

Karger

Access to resources Recommend Favorite

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: From clinical trials to clinical practice

By Sickenberg Michel  

Seminars in Ophthalmology, Vol. 16, Iss. 4, 2001-12 ,pp. : 207-212

Informa Healthcare

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

By  

Ophthalmologica, Vol. 233, Iss. 2, 2014-11 ,pp. : 66-73

Karger

Access to resources Recommend Favorite

Mitotropic Compounds for the Treatment of Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 217, Iss. 5, 2003-08 ,pp. : 351-357

Karger

Access to resources Recommend Favorite